Erythropoietin dose and survival of hemodialysis patients

Main Article Content

Mahdi Mohammadian Hamid Salehiniya Salman Khazaei Abdollah Mohammadian-Hafshejani

Abstract

Chronic kidney disease (CKD) is known as a major health problem worldwide (Levey et al., 2007). The CKD is defined as a stage of disease in which the patient's kidney function is less than a half of normal capacity (2). If the kidney function is 10% to 15% less than the normal capacity, the patient has reached the End Stage Renal Disease (ESRD). At this stage, the kidney transplant or dialysis with hemodialysis or peritoneal dialysis is necessary for patient's survival (Levey et al., 2002).

Downloads

Download data is not yet available.

Article Details

How to Cite
MOHAMMADIAN, Mahdi et al. Erythropoietin dose and survival of hemodialysis patients. Biomedical Research and Therapy, [S.l.], v. 4, n. 07, p. 1432-1434, july 2017. ISSN 2198-4093. Available at: <http://www.bmrat.org/index.php/BMRAT/article/view/195>. Date accessed: 23 oct. 2017. doi: https://doi.org/10.15419/bmrat.v4i7.195.
Section
Letter to Editor

Most read articles by the same author(s)